Brian Hutchinson

May 1, 2024 | tobaccocontrol.bmj.com | Nathan Mann |Garrison Spencer |Brian Hutchinson |Carrie J. Ngongo

WHAT IS ALREADY KNOWN ON THIS TOPIC HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Introduction Tobacco use results in premature death, illness, increased healthcare costs and economic losses.1 Numerous diseases, such as cancer, cardiovascular disease and lung disease, are caused by tobacco use.2 The life expectancy for people who smoke is up to 10 years shorter than people who do not smoke.3 Tobacco use harms people who consume tobacco products as well as people who are exposed to...

May 1, 2024 | tobaccocontrol.bmj.com | Roy Small |Rachel Nugent |Douglas Webb |Brian Hutchinson

DiscussionA careful review of the results and experiences of the authors in conducting the 21 investment cases, including feedback from in-country advocates and government officials, provides clear learnings and reflections from the multiyear effort. The investment cases appear to contribute to a diverse range of impacts and uses. FCTC 2030 countries have shown multiple tobacco control advancements that are plausibly attributable in part to the investment cases.

May 1, 2024 | tobaccocontrol.bmj.com | Rachel Nugent |Brian Hutchinson |Nathan Mann |Carrie J. Ngongo

DiscussionInvestment case methodology varies across global health topics and over time, as new models have been developed and new data become available that allow more comprehensive and country-tailored analysis. The WHO FCTC investment cases discussed in this series advance the field in several ways. Notably, they offer comparable results from a demand-driven process of strengthening tobacco control.

May 1, 2024 | tobaccocontrol.bmj.com | Garrison Spencer |Rachel Nugent |Nathan Mann |Brian Hutchinson

DiscussionBy offering country-specific evidence about the distributional effects of tobacco taxation, we show the significant differences in tobacco-attributable mortality and morbidity and resulting health and economic costs that can occur among different income groups with increases in tobacco prices.

Apr 16, 2024 | bmjopen.bmj.com | Brian Hutchinson |Adam Walter |Norm Campbell |Paul K. Whelton

DiscussionOur analysis of scaling hypertension care in 24 countries—across a range of income levels and regions—estimated that compared with continuation of the status quo improving the hypertension care cascade using an SBP≥140 mm Hg cut-point would save nearly 1.2 million lives over the study’s 30-year time horizon. It also identified that around 68% of those health benefits are derived from treating those at the highest risk (SBP≥160 mm Hg).